Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novabay Pharmaceuticals (NBY)

Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Novabay Pharmaceuticals 2000 POWELL STREET SUITE 1150 EMERYVILLE CA 94608 USA

https://novabay.com P: 510-899-8800

Description:

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus.

Key Statistics

Overview:

Market Capitalization, $K 726
Enterprise Value, $K -1,664
Shares Outstanding, K 6,529
Annual Sales, $ 14,400 K
Annual Net Income, $ -10,610 K
Last Quarter Sales, $ 3,270 K
Last Quarter Net Income, $ -1,760 K
EBIT, $ -6,900 K
EBITDA, $ 320 K
60-Month Beta 2.00
% of Insider Shareholders 1.30%
% of Institutional Shareholders 23.25%
Float, K 6,444
% Float 98.70%
Short Volume Ratio 0.50

Growth:

1-Year Return -93.49%
3-Year Return -99.67%
5-Year Return -99.70%
5-Year Revenue Growth -21.01%
5-Year Earnings Growth 39.81%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.37 on 11/09/23
Latest Earnings Date 05/09/24
Earnings Per Share ttm -6.82
EPS Growth vs. Prev Qtr 70.87%
EPS Growth vs. Prev Year 89.42%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-35 on 11/16/22

NBY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -121.42%
Return-on-Assets % -48.41%
Profit Margin % -73.68%
Debt/Equity 0.00
Price/Sales 0.06
Price/Cash Flow N/A
Price/Book 0.17
Book Value/Share 1.08
Interest Coverage -0.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar